about
Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase InhibitorsCohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) studyIncident hip fractures among community dwelling persons with Alzheimer's disease in a Finnish nationwide register-based cohortImpact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer's disease: a national population cohort studyUse of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research - the Medication use among persons with Alzheimer's disease (MEDALZ-2005) studyImpact of missing data mechanism on the estimate of change: a case study on cognitive function and polypharmacy among older persons.Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures.Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based studyFrom prescriptions to drug use periods - things to notice.Medication as a risk factor for falls: critical systematic review.From prescription drug purchases to drug use periods – a second generation method (PRE2DUP).Use of anti-dementia drugs in home care and residential care and associations with neuropsychiatric symptoms: a cross-sectional studyConcomitant use of analgesics and psychotropics in home-dwelling elderly people-Kuopio 75 + studyAgreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons.A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer's Disease in the US and Finland.Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer's disease - exposure-matched cohort study.Serum total cholesterol levels and all-cause mortality in a home-dwelling elderly population: a six-year follow-up.Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer's disease in 2005-2011.Month and Season of Birth as a Risk Factor for Alzheimer's Disease: A Nationwide Nested Case-control Study.CNS-active drugs in aging population at high risk of cerebrovascular events: evidence from preclinical and clinical studies.History of medically treated diabetes and risk of Alzheimer disease in a nationwide case-control studyIncidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer's DiseaseNumber of teeth and myocardial infarction and stroke among elderly never smokersAnalysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more.Systematic review: Use of sedatives and hypnotics, antidepressants and benzodiazepines in older people significantly increases their risk of falls.Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease.Effects of medication assessment as part of a comprehensive geriatric assessment on drug use over a 1-year period: a population-based intervention study.Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population.A comparison of four methods to quantify the cumulative effect of taking multiple drugs with sedative properties.Potentially inappropriate drug use among older persons in Finland: application of a new national categorization.Chair rise capacity and associated factors in older home-care clients.Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer's disease.Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study.No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease.Incident Use of a Potentially Inappropriate Medication and Hip Fracture in Community-Dwelling Older Persons With Alzheimer's Disease.Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease.Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study.Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer's Disease.Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study.Use of benzodiazepines and related drugs is associated with a risk of stroke among persons with Alzheimer's disease.
P50
Q26863383-917F773D-50F7-4AFE-A3FC-AF539B65986DQ28384359-921559FC-0ED6-4320-BBD0-7658FF60DD19Q28488161-D3704584-8307-45C7-AC82-5286823ACF79Q28538635-BF77D57C-AD98-4379-9488-55E9A5D5F41BQ30661806-C3E91370-E556-4EEA-8D51-59CBA89AA3FAQ30892082-ADF84253-7F7C-481B-9E73-AB1E08223944Q33160501-DC60DB19-5D90-44BD-90A3-DC96065F0CD3Q33718205-B8B78F05-6637-40BF-9361-001A925DCED1Q34551391-FB769B19-6AD8-4762-B44A-9A4C12FB6E59Q34699352-462373C6-AFF2-4BDD-A479-7701454324BEQ35246583-0E5DDFAB-6505-4E7D-A61B-20EC3A925004Q35744523-85064690-FBCF-48EA-AB1E-3967E845649AQ35826750-7CBC0DDF-67D4-4EBF-9495-982DD14C1789Q36175497-D77D1A97-6067-473A-A052-5821D9C77BF0Q36206447-5915733C-F6BF-4BAD-8A53-E84ECBFB257BQ36210640-35B06BD3-99EF-493E-8694-6F1AA2A39080Q36234146-432E8F43-510A-41BE-9C3D-12344467D0EEQ36302602-D8546130-B4E2-4A33-A84E-8C40A4327695Q36791772-767269AA-D52A-4B97-9791-48D7BA90EA96Q36864146-9DF280C5-C814-44A1-804F-ADF7DEDC8182Q36942194-42202DE3-A9CD-45DD-A8A2-6DBEE86B210AQ37053920-D20B9666-F64C-40D3-81CE-F3BE39E2CE35Q37175067-42DC8081-2A15-473F-954E-A74538790039Q37233377-5867F8E2-F7C5-4C4E-807B-58877A9C0BA0Q37740842-659AFFFE-3F3A-47BB-87C4-6463E74DC8C8Q37746403-AE767538-34D3-4EF3-A911-678DE89A0663Q37762796-528C9A74-9930-48BB-AD22-3D2FB7F42476Q37838861-6E856704-EBE0-4B9C-948C-9DAB2E0956C4Q37845005-6D0D842C-D2C8-4889-8CDA-F3C0AEB7706FQ38034443-9B25E99E-02A2-448B-B9E8-1778DBE1C021Q38374143-4F4413C4-B1F1-478F-8F73-964AFD4BB4E1Q38502957-BDF035D2-1BEE-4E21-AA44-44723F75E29AQ38648405-F1BB4DF5-C70B-46D4-97C0-2683F284827AQ38684601-4C3D941E-A92C-4C1C-9C2C-46D6B496E8CEQ38685920-A8ADD978-8FF7-4953-A44F-8ED417AF4D0FQ38747284-D161ABE2-B840-4999-BEA2-09C938FA685CQ38920215-1D8307F1-44D8-4948-A976-894F292DD547Q38986435-2A36E2B6-3E19-4265-810B-4C0A0760F22DQ39018425-A6D8B2C2-0124-4081-82DD-6720E5B34537Q39029277-3C0EA21E-BE58-4AE0-B184-80B0D3B078B6
P50
name
Sirpa Hartikainen
@ast
Sirpa Hartikainen
@en
Sirpa Hartikainen
@es
Sirpa Hartikainen
@nl
type
label
Sirpa Hartikainen
@ast
Sirpa Hartikainen
@en
Sirpa Hartikainen
@es
Sirpa Hartikainen
@nl
prefLabel
Sirpa Hartikainen
@ast
Sirpa Hartikainen
@en
Sirpa Hartikainen
@es
Sirpa Hartikainen
@nl